Valuation _老虎社区_美港股上老虎

DZL
2021-12-18

Valuation of vaccine makers dipped with uncertainty of pandemic

Why Pfizer and Johnson & Johnson Fell on Friday

What happened Two prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso

Why Pfizer and Johnson & Johnson Fell on Friday

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":699505515,"tweetId":"699505515","gmtCreate":1639830070081,"gmtModify":1639830070633,"author":{"id":3582006183410147,"idStr":"3582006183410147","authorId":3582006183410147,"authorIdStr":"3582006183410147","name":"DZL","avatar":"https://static.tigerbbs.com/640ac3ae648fded99146300a53c24a5b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":56,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Valuation of vaccine makers&nbsp;dipped with uncertainty of pandemic&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Valuation of vaccine makers&nbsp;dipped with uncertainty of pandemic&nbsp;</p></body></html>","text":"Valuation of vaccine makers dipped with uncertainty of pandemic","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/699505515","repostId":1109831591,"repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p>\n<p>Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p>\n<p><img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p>\n<p>So what</p>\n<p><b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p>\n<p>Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p>\n<p>\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p>\n<p>As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p>\n<p>\"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p>\n<p>Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p>\n<p>Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p>\n<p>Now what</p>\n<p>Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 13:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1106,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":55,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Why Pfizer and Johnson & Johnson Fell on Friday

评论（1）

热议股票